Improvement in solubility of BCS class II drug: Telmisartan
1 Associate professor; Department of Pharmaceutics, DY Patil university school of pharmacy, Mumbai, India.
2 Students; Department of Pharmaceutics, HK College of Pharmacy, Mumbai, India.
Research Article
World Journal of Biology Pharmacy and Health Sciences, 2023, 14(01), 222–230.
Article DOI: 10.30574/wjbphs.2023.14.1.0195
Publication history:
Received on 13 March 2023; revised on 21 April 2023; accepted on 24 April 2023
Abstract:
Telmisartan is used in the treatment of Hypertension (high blood pressure), prevention of heart attacks, strokes and heart failure. It is an angiotensin II type -1 receptor antagonist. Telmisartan belongs to class II under biopharmaceutical classification system. Hence, the solubility is the main issue. To increase the oral absorption, telmisartan requires enhancement in solubility and dissolution. The present study was aimed to increase the solubility of telmisartan by various techniques such as complexation and Solid dispersion. The tablet formulation was prepared to enhance the solubility and dissolution and compared with the drug release profile of the marketed preparation.
Keywords:
Hypertension; Anti-hypertensive agent; Telmisartan; BCS class II drug; Solubility enhancement; Complexation; Solid dispersion
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0